Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2018-01-11
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus and vatalanib may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving everolimus
together with vatalanib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of everolimus and
vatalanib in treating patients with advanced solid tumors.